Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma

a study on HIV/AIDS Lymphoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
estimated completion
Principal Investigator
Erin G. Reid, MD
Photo of Erin G. Reid
Erin G. Reid

Description

Summary

This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.

Official Title

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

Details

PRIMARY OBJECTIVES:

  1. Identify baseline clinical characteristics and treatment strategies in patients with AIDS-associated primary effusion lymphoma (PEL) that correlate with long-term survival (>= 2 years). (Primary clinical objective) II. Identify differentially expressed genes in PEL that are associated with long-term survival (>= 2 years). (Primary genomic objective)

OUTLINE:

Medical chart review is performed and patient information is collected regarding human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via ribonucleic acid (RNA) sequencing and microarray.

Keywords

AIDS-Related Primary Effusion Lymphoma Lymphoma Lymphoma, Primary Effusion Laboratory Biomarker Analysis Medical Chart Review Chart review, RNA sequencing, microarray

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is available
  • Participants may be enrolled to either or both the clinical or genomic portions of the study
  • The minimum data required to be able to include a subject for analysis of clinical prognostic factors are:
  • HIV status, and for HIV subjects include cluster of differentiation (CD)4 count, HIV viral load closest to time of diagnosis
  • Age at PEL diagnosis
  • Gender
  • Stage at diagnosis
  • Treatment of PEL
  • Response to treatment
  • Survival status at 2 years
  • Pathology slides (or paraffin block) for central review
  • The minimum data required to be able to include a subject for analysis of genomic prognostic factors are:
  • Availability of a pathologic specimen of PEL that will be submitted for genomic analysis
  • Survival status at 2 years

You CAN'T join if...

  • Patients who do not fulfill the criteria as listed above are ineligible

Locations

  • UC San Diego Moores Cancer Center accepting new patients
    La Jolla California 92093 United States
  • UCLA CARE Center accepting new patients
    Los Angeles California 90025 United States

Lead Scientist at UCSD

  • Erin G. Reid, MD
    Dr. Reid’s broad research interests are to develop and conduct clinical trials for hematologic malignancies. She has made significant progress in the developing a concentration on AIDS-related lymphoma and Kaposi’s sarcoma. Fellow - Hematology-Oncology, Stanford University - 2001-2003 Fellow - Hematology-Oncology, University of California, San Diego - 2004

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AIDS Malignancy Consortium
ID
NCT02823327
Study Type
Observational
Last Updated
Contact us about this trial